Prostatic artery embolization as a collaboration between urology and interventional radiology
“One thing that from the very beginning we talked about is how can we push this forward? How can we think outside the box and take this to the next level to make an impact for our patients?” says Katie Murray, DO, MS.
In this video, Katie Murray, DO, MS, and Kimberly Kocour, MD, share the take-home message from the South Central Section of the AUA Annual Meeting abstract, "Prostatic artery embolization: an option for select male patients with necessary collaboration between urology and interventional radiology." Murray is an assistant professor at the University of Missouri Division of Urology in Columbia. Kocour is a urology resident at the University of Missouri.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
